<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1974">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05135468</url>
  </required_header>
  <id_info>
    <org_study_id>CU-40102-303</org_study_id>
    <nct_id>NCT05135468</nct_id>
  </id_info>
  <brief_title>A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Clinical Study Patients With Androgenetic Alopecia (AGA)</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Finasteride Spray (CU-40102) in Chinese Adult Male Patients With Androgenetic Alopecia (AGA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cutia Therapeutics（Wuxi）Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cutia Therapeutics（Wuxi）Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Clinical Study ,the&#xD;
      mean change from baseline in vertex target area hair count (TAHC) after treatment for 24&#xD;
      weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Drug:0.25% (2.275mg/mL) Finasteride Spray Placebo for CU-40102 Spray</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TAHC</measure>
    <time_frame>24 weeks.</time_frame>
    <description>the change from baseline in target area hair count (TAHC) in the vertex after treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>AGA</condition>
  <arm_group>
    <arm_group_label>CU-40102 Spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.25% (2.275mg/mL) Finasteride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for CU-40102 Spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CU-40102 Spray</intervention_name>
    <description>topical application, 1~4 sprays each time, once daily</description>
    <arm_group_label>CU-40102 Spray</arm_group_label>
    <arm_group_label>Placebo for CU-40102 Spray</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Having voluntarily signed the ICF approved by the Ethics Committee and consented to&#xD;
             participate in this study before starting any study procedure;&#xD;
&#xD;
          2. Being able to understand and comply with the requirements of the protocol and agreeing&#xD;
             to participate in all study visits;&#xD;
&#xD;
          3. Males aged 18 to 41 years (inclusive);&#xD;
&#xD;
          4. Being diagnosed with Type III vertex, Type IV or Type V androgenetic alopecia (AGA)&#xD;
             according to the Hamilton-Norwood classification (see Appendix 1 for details);&#xD;
&#xD;
          5. Appropriate medical contraceptive methods being used to prevent the sexual partner&#xD;
             from becoming pregnant from the time of signing ICF to 28 days after the last dose; -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A history of scalp skin abnormalities or scalp skin diseases at the time of screening&#xD;
&#xD;
          2. Patients with secondary alopecia such as those associated with malnutrition, drugs,&#xD;
             endocrine , iron deficiency anemia, or systemic lupus erythematosus;&#xD;
&#xD;
          3. Patients with alopecia areata, alopecia cicatrisata, or trichotillomania;&#xD;
&#xD;
          4. Having undergone hair transplantation or extension before screening, or persistent&#xD;
             requirement to wear a wig sheath during study treatments;&#xD;
&#xD;
          5. Known allergy to the active ingredient of the investigational drug or any component of&#xD;
             the excipients, or to any component of the tattoo liquid;&#xD;
&#xD;
          6. A history of depression, anxiety, personality disorder or other mental disorders;&#xD;
&#xD;
          7. A history of varicocele or infertility ;&#xD;
&#xD;
          8. A history of malignant tumor;&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>41 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tracy Jin</last_name>
    <phone>02152983119</phone>
    <email>medical.co@cutiatx.com</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 16, 2021</study_first_submitted>
  <study_first_submitted_qc>November 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

